| . | Number (%) or mean (s.d.) . |
|---|---|
| (n = 508 patients) . | |
| Female | 460 (92%) |
| Age at diagnosis (years) | 40.7 (21.0) |
| Disease duration at enrolment (years) | 10.8 (9.9) |
| Age at enrolment (years) | 50.4 (13.7) |
| 2012 SLICC criteria (ever present) | |
| Clinical criteria | |
| Acute cutaneous lupus | 262 (51.8%) |
| Chronic cutaneous lupus | 57 (11.2%) |
| Oral or nasal ulcers | 171 (33.7%) |
| Non-scaring alopecia | 156 (30.7%) |
| Arthritis | 355 (69.9%) |
| Serositis | 96 (18.9%) |
| Renal disorder | 158 (31.1%) |
| Neurologic disorder | 32 (6.3%) |
| Hemolytic anaemia | 29 (5.7%) |
| Leukopenia | 219 (43.1%) |
| Thrombocytopenia | 88 (17.3%) |
| Immunological criteria | |
| Antinuclear antibody | 489 (96.3%) |
| Anti-dsDNA antibodies | 329 (64.8%) |
| Anti-Sm antibodies | 95 (18.7%) |
| Anti-phospholipid antibodies | 163 (32.1%) |
| Low complement levels | 306 (60.2%) |
| Other disease characteristics at enrolment | |
| Number of ACR criteria for SLE | 5 (1.5) |
| Number of SLICC criteria for SLE | 6.24 (2.2) |
| SLEDAI-2K score | 2.8 (3.3) |
| SLICC/ACR-DI score | 0.96 (1.4) |
| Damage present | 253 (49.8%) |
| Clinical SLEDAI-2 K (not including complement or anti-dsDNA level) | 1.6 () |
| Hypocomplementemia | 152(29.9%) |
| Elevated anti-dsDNA | 125 (24.6%) |
| Physician Global Assessment score | 0.2 (0.49) |
| . | Number (%) or mean (s.d.) . |
|---|---|
| (n = 508 patients) . | |
| Female | 460 (92%) |
| Age at diagnosis (years) | 40.7 (21.0) |
| Disease duration at enrolment (years) | 10.8 (9.9) |
| Age at enrolment (years) | 50.4 (13.7) |
| 2012 SLICC criteria (ever present) | |
| Clinical criteria | |
| Acute cutaneous lupus | 262 (51.8%) |
| Chronic cutaneous lupus | 57 (11.2%) |
| Oral or nasal ulcers | 171 (33.7%) |
| Non-scaring alopecia | 156 (30.7%) |
| Arthritis | 355 (69.9%) |
| Serositis | 96 (18.9%) |
| Renal disorder | 158 (31.1%) |
| Neurologic disorder | 32 (6.3%) |
| Hemolytic anaemia | 29 (5.7%) |
| Leukopenia | 219 (43.1%) |
| Thrombocytopenia | 88 (17.3%) |
| Immunological criteria | |
| Antinuclear antibody | 489 (96.3%) |
| Anti-dsDNA antibodies | 329 (64.8%) |
| Anti-Sm antibodies | 95 (18.7%) |
| Anti-phospholipid antibodies | 163 (32.1%) |
| Low complement levels | 306 (60.2%) |
| Other disease characteristics at enrolment | |
| Number of ACR criteria for SLE | 5 (1.5) |
| Number of SLICC criteria for SLE | 6.24 (2.2) |
| SLEDAI-2K score | 2.8 (3.3) |
| SLICC/ACR-DI score | 0.96 (1.4) |
| Damage present | 253 (49.8%) |
| Clinical SLEDAI-2 K (not including complement or anti-dsDNA level) | 1.6 () |
| Hypocomplementemia | 152(29.9%) |
| Elevated anti-dsDNA | 125 (24.6%) |
| Physician Global Assessment score | 0.2 (0.49) |
dsDNA: double-stranded DNA; SLEDAI: SLE disease activity index; SLICC: Systemic Lupus International Collaborating Clinics; SLICC/ACR-DI: SLICC/ACR Damage Index.
aRecorded at enrolment on an ‘ever present’ basis.
| . | Number (%) or mean (s.d.) . |
|---|---|
| (n = 508 patients) . | |
| Female | 460 (92%) |
| Age at diagnosis (years) | 40.7 (21.0) |
| Disease duration at enrolment (years) | 10.8 (9.9) |
| Age at enrolment (years) | 50.4 (13.7) |
| 2012 SLICC criteria (ever present) | |
| Clinical criteria | |
| Acute cutaneous lupus | 262 (51.8%) |
| Chronic cutaneous lupus | 57 (11.2%) |
| Oral or nasal ulcers | 171 (33.7%) |
| Non-scaring alopecia | 156 (30.7%) |
| Arthritis | 355 (69.9%) |
| Serositis | 96 (18.9%) |
| Renal disorder | 158 (31.1%) |
| Neurologic disorder | 32 (6.3%) |
| Hemolytic anaemia | 29 (5.7%) |
| Leukopenia | 219 (43.1%) |
| Thrombocytopenia | 88 (17.3%) |
| Immunological criteria | |
| Antinuclear antibody | 489 (96.3%) |
| Anti-dsDNA antibodies | 329 (64.8%) |
| Anti-Sm antibodies | 95 (18.7%) |
| Anti-phospholipid antibodies | 163 (32.1%) |
| Low complement levels | 306 (60.2%) |
| Other disease characteristics at enrolment | |
| Number of ACR criteria for SLE | 5 (1.5) |
| Number of SLICC criteria for SLE | 6.24 (2.2) |
| SLEDAI-2K score | 2.8 (3.3) |
| SLICC/ACR-DI score | 0.96 (1.4) |
| Damage present | 253 (49.8%) |
| Clinical SLEDAI-2 K (not including complement or anti-dsDNA level) | 1.6 () |
| Hypocomplementemia | 152(29.9%) |
| Elevated anti-dsDNA | 125 (24.6%) |
| Physician Global Assessment score | 0.2 (0.49) |
| . | Number (%) or mean (s.d.) . |
|---|---|
| (n = 508 patients) . | |
| Female | 460 (92%) |
| Age at diagnosis (years) | 40.7 (21.0) |
| Disease duration at enrolment (years) | 10.8 (9.9) |
| Age at enrolment (years) | 50.4 (13.7) |
| 2012 SLICC criteria (ever present) | |
| Clinical criteria | |
| Acute cutaneous lupus | 262 (51.8%) |
| Chronic cutaneous lupus | 57 (11.2%) |
| Oral or nasal ulcers | 171 (33.7%) |
| Non-scaring alopecia | 156 (30.7%) |
| Arthritis | 355 (69.9%) |
| Serositis | 96 (18.9%) |
| Renal disorder | 158 (31.1%) |
| Neurologic disorder | 32 (6.3%) |
| Hemolytic anaemia | 29 (5.7%) |
| Leukopenia | 219 (43.1%) |
| Thrombocytopenia | 88 (17.3%) |
| Immunological criteria | |
| Antinuclear antibody | 489 (96.3%) |
| Anti-dsDNA antibodies | 329 (64.8%) |
| Anti-Sm antibodies | 95 (18.7%) |
| Anti-phospholipid antibodies | 163 (32.1%) |
| Low complement levels | 306 (60.2%) |
| Other disease characteristics at enrolment | |
| Number of ACR criteria for SLE | 5 (1.5) |
| Number of SLICC criteria for SLE | 6.24 (2.2) |
| SLEDAI-2K score | 2.8 (3.3) |
| SLICC/ACR-DI score | 0.96 (1.4) |
| Damage present | 253 (49.8%) |
| Clinical SLEDAI-2 K (not including complement or anti-dsDNA level) | 1.6 () |
| Hypocomplementemia | 152(29.9%) |
| Elevated anti-dsDNA | 125 (24.6%) |
| Physician Global Assessment score | 0.2 (0.49) |
dsDNA: double-stranded DNA; SLEDAI: SLE disease activity index; SLICC: Systemic Lupus International Collaborating Clinics; SLICC/ACR-DI: SLICC/ACR Damage Index.
aRecorded at enrolment on an ‘ever present’ basis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
